Bevacizumab, Pertuzumab, And Sandostatin For Patients (Pts) With Advanced Neuroendocrine Cancers (Net)

Irfan Firdaus,Kent C. Shih,Ahmed Zakari, Evan Z. Lang,Michael McCleod, Kathryn B. Alguire,Nancy Walker Peacock, Douglas B. Flora,Peter Ruehlman,Chris Earwood,Johanna C. Bendell

JOURNAL OF CLINICAL ONCOLOGY（2012）

引用 30|浏览22

暂无评分

摘要

4127 Background: Targeted agents are used to treat well-differentiated NET. Octreotide binds somatostatin receptors and improves time to progression (TTP) of carcinoid tumors, and VEGF pathway targ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要